The stock of Novo Nordisk A S (ADR) (NYSE:NVO) is a huge mover today! About 753,894 shares traded hands. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 42.93% since April 25, 2016 and is downtrending. It has underperformed by 48.94% the S&P500.
The move comes after 9 months positive chart setup for the $66.57 billion company. It was reported on Nov, 28 by Barchart.com. We have $34.47 PT which if reached, will make NYSE:NVO worth $3.99 billion more.
Analysts await Novo Nordisk A S (ADR) (NYSE:NVO) to report earnings on February, 1. They expect $0.52 earnings per share, up 10.64% or $0.05 from last year’s $0.47 per share. NVO’s profit will be $1.06B for 15.63 P/E if the $0.52 EPS becomes a reality. After $0.58 actual earnings per share reported by Novo Nordisk A S (ADR) for the previous quarter, Wall Street now forecasts -10.34% negative EPS growth.
Novo Nordisk A S (ADR) (NYSE:NVO) Ratings Coverage
Out of 13 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 3 rate it a “Buy”, 2 “Sell”, while 8 “Hold”. This means 23% are positive. Novo Nordisk (ADR) has been the topic of 13 analyst reports since August 28, 2015 according to StockzIntelligence Inc. The firm has “Conviction Buy” rating given on Monday, February 15 by Goldman Sachs. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) has “Market Perform” rating given on Friday, August 28 by Leerink Swann. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) has “Hold” rating given on Monday, October 31 by DNB Markets. The firm has “Hold” rating by HSBC given on Wednesday, August 31. Zacks upgraded the stock to “Hold” rating in Friday, August 28 report. The company was downgraded on Friday, September 9 by JP Morgan. On Tuesday, September 13 the stock rating was upgraded by BNP Paribas to “Outperform”. The firm earned “Neutral” rating on Monday, October 31 by Citigroup. The company was initiated on Friday, September 23 by Piper Jaffray. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) has “Sell” rating given on Monday, February 8 by UBS.
According to Zacks Investment Research, “Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world’s largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.”
More recent Novo Nordisk A S (ADR) (NYSE:NVO) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on July 03, 2009. Also Quotes.Wsj.com published the news titled: “DOW JONES, A NEWS CORP COMPANY” on February 11, 2011. Investorplace.com‘s news article titled: “Why American Airlines Group Inc (AAL), Novo Nordisk A/S (ADR) (NVO) and …” with publication date: June 14, 2016 was also an interesting one.
NVO Company Profile
Novo Nordisk A/S, incorporated on November 28, 1931, is a healthcare company. The Firm is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business divisions include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.